Rats were administered SNC80 to study the role of nitric oxide synthase in peripheral antinociception mechanism.5
Biochem/physiol Actions
SNC80 is a δ opioid receptor agonist.
SNC80 is a highly selective agonist of δ opioid receptor but also binds to μ-δ opioid receptor heteromers to produce antinociception in mice.2 It also acts as anti-depressant3, elicits dopamine-related behaviors and enhances behavioral responses to psychostimulants.4
Features and Benefits
This compound is featured on the Opioid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
The Journal of pharmacology and experimental therapeutics, 335(1), 133-139 (2010-07-08)
Alcoholism and anxiety disorders have a huge impact on society and afflict 17.6 million and 40 million people in the United States, respectively. A strong comorbidity exists between alcoholism and anxiety disorders. Indeed, alcohol withdrawal-induced anxiety is a primary contributing
The delta opioid receptor (DOR) has raised much interest for the development of new therapeutic drugs, particularly to treat patients suffering from mood disorders and chronic pain. Unfortunately, the prototypal DOR agonist SNC80 induces mild epileptic seizures in rodents. Although
Response inhibition, a primary symptom of many psychiatric disorders, is mediated through a complex neuropharmacological network that involves dopamine, serotonin, glutamate, noradrenaline, and cannabinoid mechanisms. Recently, we identified an opioidergic contribution to response inhibition by showing that deletion of mu
Journal of medicinal chemistry, 40(5), 695-704 (1997-02-28)
The highly selective delta (delta) opioid receptor agonist SNC 80 [(+)-4- [(alpha R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N ,N- diethylbenzamide, (+)-21] and novel optically pure derivatives were synthesized from the enantiomers of 1-allyl-trans-2,5-dimethylpiperazine (2). The piperazine (+/-)-2 was synthesized, and its enantiomers were obtained on
The Journal of pharmacology and experimental therapeutics, 342(3), 799-807 (2012-06-16)
N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5859) and N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl)benzamide (ADL5747) are novel δ-opioid agonists that show good oral bioavailability and analgesic and antidepressive effects in the rat and represent potential drugs for chronic pain treatment. Here, we used genetic approaches to investigate molecular mechanisms
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
![[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt ≥97% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/227/014/768064c2-9ae6-47bd-8550-e2aa5c3b61de/640/768064c2-9ae6-47bd-8550-e2aa5c3b61de.png)
![[D-Ala2, D-Leu5]-Enkephalin acetate salt ≥95% (HPLC)](/deepweb/assets/sigmaaldrich/product/structures/934/176/d990e568-42df-43e9-a231-da7a3d9d7687/640/d990e568-42df-43e9-a231-da7a3d9d7687.png)
